WR
MACK

Watson Rebecca’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Watson Rebecca’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,068
Closed -$10K – 382
2020
Q2 		$10K Buy
+3,068
New +$10.5K 0.01% 262

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Watson Rebecca's MACK Position: Q3 2020 in Review

Watson Rebecca sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2020, closing a stake of 3,068 shares — an estimated $10K sold.

Watson Rebecca first reported a position in MACK in Q2 2020 and held it in 1 quarter. The position peaked at $10K in Q2 2020. 38 funds tracked by Wall St. Rank hold MACK as of Q3 2020.

  • Watson Rebecca reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Watson Rebecca sold 3,068 Merrimack Pharmaceuticals, Inc. shares in Q3 2020, an estimated $10K.
  • Watson Rebecca first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Watson Rebecca's Merrimack Pharmaceuticals, Inc. position peaked at $10K in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2020.

Based on Watson Rebecca's 13F filing for Q3 2020, filed 22 Oct 2020.